Novel approach to CAR T cell therapy at UPenn Center for Cellular Immunotherapies

October 4, 2016 Christoph Graener

Avery Posey, Instructor at the Center for Cellular Immunotherapies at the University of Pennsylvania is interviewed by Samuel Murphy, Managing Partner at BioPharma Capital, Inc., about his work in CAR T cell therapy and next generation approaches involving glycoproteins combined with protein targets for tumor targeting.

Interviewer: Samuel Murphy – Managing Partner, BioPharma Capital, Inc.
Interviewee: Avery Posey – Instructor, Center for Cellular Immunotherapies,
University of Pennsylvania

Previous Article
ContraVir conducting Phase II studies for combination therapy in HBV

ContraVir CEO James Sapirstein discusses his company's plans to improve on current therapies for hepatitis ...

Next Article
Cloud computing is the secret to Cloud Pharmaceuticals’ drug discovery

Cloud Pharmaceuticals uses cloud computing to accelerate the discovery and design of novel small-molecule d...